Pay in 4 interest-free payments of $5.98 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist marketed as Ozempic, Wegovy, and Rybelsus, does not typically appear on standard blood tests ordered during routine medical care
Rybelsus (semaglutide) is a GLP-1 receptor agonist and represents a significant advancement in type 2 diabetes treatment as the first oral medication in this therapeutic class
***Based on a 6-month clinical trial (n=180) of individuals who were enrolled between FebruaryApril 2024, with overweight or obesity taking semaglutide or tirzepatide for weight loss and related outcomes through the WW Clinic Program and participating in the GLP-1 companion nutrition program
Semaglutide has a half-life of approximately one week, meaning it takes about seven days for half the medication to clear your body
